ACA
AXSM icon

American Capital Advisory’s Axsome Therapeutics AXSM Stock Holding History

American Capital Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$1.23K – 444
2024
Q1 		$1.23K Buy
+20
New +$1.68K ﹤0.01% 387

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Capital Advisory's AXSM Position: Q2 2024 in Review

American Capital Advisory sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 20 shares — an estimated $1.23K sold.

American Capital Advisory first reported a position in AXSM in Q1 2024 and held it in 1 quarter. The position peaked at $1.23K in Q1 2024. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • American Capital Advisory reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American Capital Advisory sold 20 Axsome Therapeutics shares in Q2 2024, an estimated $1.23K.
  • American Capital Advisory first reported a position in Axsome Therapeutics in Q1 2024 and held it in 1 quarter.
  • American Capital Advisory's Axsome Therapeutics position peaked at $1.23K in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on American Capital Advisory's 13F filing for Q2 2024, filed 29 Jul 2024.